Navigation Links
Peptimmune Announces Grant of United States Patent for PI-2301 Peptide Copolymer for Multiple Sclerosis
Date:7/30/2008

CAMBRIDGE, Mass., July 30 /PRNewswire/ -- Peptimmune, Inc. a privately held biotechnology company, announced today the grant of US Patent Number 7,381,790 (the '790 patent) which protects the composition of matter for its PI-2301 peptide copolymer for the treatment of autoimmune diseases.

PI-2301 is currently in a Phase Ib multiple-ascending dose, double-blind, placebo-controlled randomized study in subjects with multiple sclerosis. Following establishment of safety at potentially therapeutic doses and proof of pharmacologic mechanism, the Company plans to initiate its Phase II study in relapsing remitting multiple sclerosis patients in early 2009.

"This patent represents an important component in the development of our intellectual property in peptide copolymers, including PI-2301," stated Thomas P. Mathers, President and CEO of Peptimmune. "The '790 patent protects what we believe may become a very important therapy for the treatment of multiple sclerosis and other autoimmune diseases."

PI-2301 is a second-generation peptide copolymer from a similar compound class as Copaxone(R) (Teva Pharmaceuticals). PI-2301 has been designed to be more efficacious and more convenient (weekly versus daily dosing) than Copaxone for the treatment of multiple sclerosis. PI-2301 works through immune modulation by enhancing the regulatory response of the immune system and thereby controlling the pathogenic autoimmune response observed in some diseases. In a Phase I single ascending dose, double blind placebo controlled randomized study, all doses of PI-2301 were safe and well tolerated, and no serious adverse events were observed. Pharmacodynamic assays demonstrated evidence of immune exposure consistent with the pharmacologic mechanism of action for PI-2301, and dose-dependent pharmacokinetics was observed.

PI-2301 has been optimized using Peptimmune's novel platform peptide chemistry and, in preclinical studies, has shown to be more potent and eff
'/>"/>

SOURCE Peptimmune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Peptimmune Initiates Phase I Study With a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis
2. Peptimmune Completes Phase I Study with a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis
3. Peptimmune Presents Early Clinical Data at European Neurological Society and Federation of Clinical Immunology Societies Meetings
4. Peptimmune Initiates Phase Ib Study of PI-2301 in Multiple Sclerosis Patients and Presentation at BIO 2008
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 4, 2015 PTC Therapeutics, Inc. (NASDAQ: PTCT ... for the first quarter ending March 31, 2015. ... In our first full quarter since the commercial launch, we ... treatment for nonsense mutation Duchene Muscular Dystrophy. We now have ... treatment since our last earnings call," stated Stuart W. ...
(Date:5/4/2015)... May 4, 2015 Transportation Insight, a ... electronics distributor client, DSI Systems Inc., are featured ... magazine in the cover story emphasizing technology ... The editorial illustrates how Transportation Insight ... manage the growth and success of DSI,s complex ...
(Date:5/4/2015)... The New York Times sought out medical insight ... Dr. Rod Rohrich . Kybella, recently approved by ... fat deposits under the chin. Photo - ... in Kybella, deoxycholic acid, dissolves the fat under the ... this area without surgery. "So many consumers don,t want ...
Breaking Medicine Technology:PTC Therapeutics Reports First Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports First Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports First Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports First Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports First Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports First Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports First Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports First Quarter 2015 Financial Results and Provides Corporate Update 9Transportation Insight's Latest Enterprise Logistics Technology Highlighted in Inbound Logistics Magazine 2Transportation Insight's Latest Enterprise Logistics Technology Highlighted in Inbound Logistics Magazine 3Dr. Rod Rohrich Provides Medical Expertise on Kybella 2Dr. Rod Rohrich Provides Medical Expertise on Kybella 3
... HASCO Medical, Inc. (OTC Bulletin Board: HASC ... serves patients in Alabama, Florida, and Mississippi, today announced ... subsidiary of HASCO Medical, has signed an agreement with ... of the agreement, SMM will be providing high-end rehabilitation chairs ...
... NEW YORK, Jan. 13, 2011 Reportlinker.com announces ... in its catalogue: Merck & ... http://www.reportlinker.com/p074950/Merck--Co-Inc-PharmaVitae-Profile.html IntroductionThis analysis examines ... Co. in the prescription pharmaceutical sector. The profile ...
Cached Medicine Technology:HASCO Medical Signs Agreement With the State of Alabama 2Reportlinker Adds Merck & Co., Inc.: PharmaVitae Profile 2
(Date:5/4/2015)... and Seattle, WA (PRWEB) May 04, 2015 ... formation of a collaboration to facilitate development of NM108, ... ophthalmic disorders that lead to blindness, including Diabetic Retinopathy. ... MiDROPS™ formulation platform developed by EyeCRO, which can deliver ... via a topical eyedrop. , Under the terms ...
(Date:5/4/2015)... Charlottesville, VA (PRWEB) May 04, 2015 Ticket ... tickets at the John Paul Jones Arena in Charlottesville, ... in the history of the music business and this beloved ... down. Paul McCartney, the former member of two legendary groups: ... decades in the music business since 2013 on the “Out ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 New findings ... Brain Tumor Association (ABTA) show that people diagnosed with ... and treatment options, including clinical trials, at the time ... to make difficult decisions about their course of treatment. ... of the first nationwide brain tumor volunteer network, the ...
(Date:5/4/2015)... Pricing Healthcare announces it will ... patient receiving care at St. George Surgical Center ... be performed by July 15th, 2015, and the patient must ... front and forego the filing of insurance claims). , The ... year, and it devastates more and more individuals and families. ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 Sheltering Arms ... Center from Hale House. The Mother Hale Learning Center ... affordable Early Childhood Education. Sheltering Arms will begin operating ... to be served by the center. , Opened in ... ages six weeks to five years, many of whom ...
Breaking Medicine News(10 mins):Health News:EyeCRO and NeuMedics Announce Collaboration to Utilize MiDROPS™ Technology for the Development of NM108 2Health News:EyeCRO and NeuMedics Announce Collaboration to Utilize MiDROPS™ Technology for the Development of NM108 3Health News:Paul McCartney Tickets at John Paul Jones Arena in Charlottesville, VA: Ticket Down Slashes Paul McCartney Ticket Prices in Charlottesville at the John Paul Jones Arena 2Health News:American Brain Tumor Association Poll Underscores Need for Greater Awareness and Education at Time of Diagnosis 2Health News:American Brain Tumor Association Poll Underscores Need for Greater Awareness and Education at Time of Diagnosis 3Health News:Pricing Healthcare to Pay a Patient's Bill for a Procedure at Utah Facility 2Health News:Pricing Healthcare to Pay a Patient's Bill for a Procedure at Utah Facility 3Health News:Sheltering Arms Acquires the Mother Hale Learning Center 2
... FRANCISCO, Calif., Oct. 5 Exelixis,Inc. (Nasdaq: EXEL ... of research and development, will present at the 2007,BIO ... (EDT) on,Wednesday, October 10, 2007. The presentation will ... page under Investors on the Exelixis website at, http://www.exelixis.com ...
... -- conference call and audio web cast on October 9, 2007 --, BELLEVILLE, ON, Oct. ... U.S. Department of Agriculture,(USDA) comment on a field trial for its E. coli O157:H7 cattle vaccine,during ... Conference Call & Audio Web Cast ... Tuesday, October 9, 2007 ...
... creating an effective drug: finding a chemical compound that ... then delivering it to the right place in the ... support from a $478,000, five-year CAREER award from the ... part of this problem. She is creating a modular, ...
... and ASSAGO MI, Italy, Oct. 5 GENICON,and SIAD ... strategic,partnership. Under this new partnership, SIAD Healthcare S.p.A. has ... SIAD Healthcare,S.p.A. will have a position on GENICON,s Board ... of Yale University. In August of 2006, GENICON ...
... experts say , , FRIDAY, Oct. 5 (HealthDay News) -- ... to eat no more than 12 ounces of fish ... have been confused, and fish consumption has dropped. , ... by the U.S. Food and Drug Administration and the ...
... job done, study shows , FRIDAY, Oct. 5 (HealthDay News) -- ... insects, a new study reveals. , Cycads, a group of plants ... years, look similar to ferns or palms but are not related ... coniferous tress such as pines and firs. , Reporting in the ...
Cached Medicine News:Health News:Developing a modular, nanoparticle drug delivery system 2Health News:Developing a modular, nanoparticle drug delivery system 3Health News:SIAD Healthcare S.p.A. Acquires Minority Ownership in GENICON 2Health News:Fish Safe for Pregnant Women to Eat 2Health News:Fish Safe for Pregnant Women to Eat 3
Prostate biopsy transducer....
Multi-frequency, HST, linear transducer with a longer (60mm) footprint. Available with puncture adapter and water path. This transducer incorporates ALOKAs exclusive Hemispheric Sound Technology and ...
... Linear high frequency ... breast and superficial ... exclusive Hemispheric Sound ... technologies. This multi-frequency ...
... an excellent choice for a ... wide scan angle. With muliple ... designed for a wide view ... versatility of this transducer provides ...
Medicine Products: